Australian Clinical Labs (ASX:ACL) EBITDA Margin % : 21.89% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Australian Clinical Labs's EBITDA for the six months ended in Dec. 2023 was A$73.9 Mil. Australian Clinical Labs's Revenue for the six months ended in Dec. 2023 was A$337.8 Mil. Therefore, Australian Clinical Labs's EBITDA margin for the quarter that ended in Dec. 2023 was 21.89%.

Australian Clinical Labs EBITDA Margin % Historical Data

The historical data trend for Australian Clinical Labs's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs EBITDA Margin % Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

EBITDA Margin %

28.95

36.63

25.23

Australian Clinical Labs Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial			43.49	28.44	25.86	24.52	21.89

Competitive Comparison of Australian Clinical Labs's EBITDA Margin %

For the Diagnostics & Research subindustry, Australian Clinical Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australian Clinical Labs's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Australian Clinical Labs's EBITDA Margin % falls into.

Australian Clinical Labs EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Australian Clinical Labs's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	174.605	/	692.103
	=	25.23 %

Australian Clinical Labs's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	73.936	/	337.816
	=	21.89 %

Australian Clinical Labs (ASX:ACL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Australian Clinical Labs EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs (ASX:ACL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs (ASX:ACL) Headlines

No Headlines